Table 2.

Investigational antibody therapeutics in regulatory review in the European Union or the United States*.

International non-proprietary name	Brand name proposed	Target; Format	Indication	Status in EU	Status in US
Sacituzumab govitecan	(Pending)	TROP-2; humanized IgG1 ADC	Triple-negative breast cancer	NA	In review
Ravulizumab (ALXN1210)	(Pending)	C5; humanized IgG2/4	Paroxysmal nocturnal hemoglobinuria	In review	In review
Risankizumab	(Pending)	IL-23 p19; Humanized IgG1	Plaque psoriasis	In review	In review
Romosozumab	EVENITY	Sclerostin; Humanized IgG2	Osteoporosis in postmenopausal women at increased risk of fracture	In review	In review

Data available as of November 30, 2018. *Antibody therapeutics not previously approved in the EU or US for any indication; biosimilar products were excluded. Abbreviations: ADC, antibody-drug conjugate; EU, European Union; C5, complement component 5; IgG, immunoglobulin G; IL, interleukin; NA, not applicable; TROP-2, trophoblast cell-surface antigen 2; US, United States.